publish positive editorial about Harvard’s nature published paper bringing additional external validation to IOME Bio’ science. READ
HOME
Mission: IOME Bio aims to harness unique mechanistic insights to overcome resistance to checkpoint inhibitors and deliver meaningful benefits for cancer patients
SCIENCE
IOME Bio builds on foundational insights and IP from world-renowned immuno-oncology researchers, and has an exclusive option to licence new IP arising from ongoing sponsored research at Harvard
ABOUT US
We are a venture-backed Harvard spin-off pursuing novel immuno-oncology targets with first-in-class antibodies
Our foundational science was discovered by Arlene Sharpe and Dennis Kasper at Harvard, and Gordon Freeman at the Dana-Farber Cancer Institute
We are addressing resistance to PD-1 blockade through proprietary mechanistic insights
We are centrally located in the beautiful city of Strasbourg, embedded in a vibrant health innovation ecosystem.
CONTACT
OUR LATEST NEWS
IOME BIO’S FOUNDATIONAL SCIENCE PUBLISHED IN NATURE
represents significant breakthrough in cancer research … Read More
New Offices and Labs
On September 13 IOME Bio organized the inauguration of its laboratories now established within the Paul Strauss Center, in the heart of Strasbourg. This was an opportunity for the Managing Director, Sarah Holland, to thank all the partners in the … Read More